Date: 2014-01-06
Type of information: Company acquisition
Acquired company: Okapi Sciences (Belgium)
Acquiring company: Aratana Therapeutics (USA)
Amount: undisclosed
Terms: * On January 6, 2014, Aratana Therapeutics, a US biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, has announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.
Details: The strategic acquisition of Okapi further enhances Aratana’s leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel Technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Related: Veterinary medicine
